Cargando…
Establishing the Medical Actionability of Genomic Variants
Actionability is an important concept in medicine that does not have a well-accepted standard definition, nor is there a general consensus on how to establish it. Medical actionability is often conflated with clinical utility, a related but distinct concept. This lack of clarity contributes to pract...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184682/ https://www.ncbi.nlm.nih.gov/pubmed/35363504 http://dx.doi.org/10.1146/annurev-genom-111021-032401 |
_version_ | 1785042194016501760 |
---|---|
author | Goddard, Katrina A.B. Lee, Kristy Buchanan, Adam H. Powell, Bradford C. Hunter, Jessica Ezzell |
author_facet | Goddard, Katrina A.B. Lee, Kristy Buchanan, Adam H. Powell, Bradford C. Hunter, Jessica Ezzell |
author_sort | Goddard, Katrina A.B. |
collection | PubMed |
description | Actionability is an important concept in medicine that does not have a well-accepted standard definition, nor is there a general consensus on how to establish it. Medical actionability is often conflated with clinical utility, a related but distinct concept. This lack of clarity contributes to practice variation and inconsistent coverage decisions in genomic medicine, leading to the potential for systematic bias in the use of evidence-based interventions. We clarify how medical actionability and clinical utility are distinct and then discuss the spectrum of actionability, including benefits for the person, the family, and society. We also describe applications across the life course, including prediction, diagnosis, and treatment. Current challenges in assessing the medical actionability of identified genomic variants include gaps in the evidence, limited contexts with practice guidelines, and subjective aspects of medical actionability. A standardized and authoritative assessment of medical actionability is critical to implementing genomic medicine in a fashion that improves population health outcomes and reduces health disparities. |
format | Online Article Text |
id | pubmed-10184682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-101846822023-05-15 Establishing the Medical Actionability of Genomic Variants Goddard, Katrina A.B. Lee, Kristy Buchanan, Adam H. Powell, Bradford C. Hunter, Jessica Ezzell Annu Rev Genomics Hum Genet Article Actionability is an important concept in medicine that does not have a well-accepted standard definition, nor is there a general consensus on how to establish it. Medical actionability is often conflated with clinical utility, a related but distinct concept. This lack of clarity contributes to practice variation and inconsistent coverage decisions in genomic medicine, leading to the potential for systematic bias in the use of evidence-based interventions. We clarify how medical actionability and clinical utility are distinct and then discuss the spectrum of actionability, including benefits for the person, the family, and society. We also describe applications across the life course, including prediction, diagnosis, and treatment. Current challenges in assessing the medical actionability of identified genomic variants include gaps in the evidence, limited contexts with practice guidelines, and subjective aspects of medical actionability. A standardized and authoritative assessment of medical actionability is critical to implementing genomic medicine in a fashion that improves population health outcomes and reduces health disparities. 2022-08-31 2022-04-01 /pmc/articles/PMC10184682/ /pubmed/35363504 http://dx.doi.org/10.1146/annurev-genom-111021-032401 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See credit lines of images or other third-party material in this article for license information |
spellingShingle | Article Goddard, Katrina A.B. Lee, Kristy Buchanan, Adam H. Powell, Bradford C. Hunter, Jessica Ezzell Establishing the Medical Actionability of Genomic Variants |
title | Establishing the Medical Actionability of Genomic Variants |
title_full | Establishing the Medical Actionability of Genomic Variants |
title_fullStr | Establishing the Medical Actionability of Genomic Variants |
title_full_unstemmed | Establishing the Medical Actionability of Genomic Variants |
title_short | Establishing the Medical Actionability of Genomic Variants |
title_sort | establishing the medical actionability of genomic variants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184682/ https://www.ncbi.nlm.nih.gov/pubmed/35363504 http://dx.doi.org/10.1146/annurev-genom-111021-032401 |
work_keys_str_mv | AT goddardkatrinaab establishingthemedicalactionabilityofgenomicvariants AT leekristy establishingthemedicalactionabilityofgenomicvariants AT buchananadamh establishingthemedicalactionabilityofgenomicvariants AT powellbradfordc establishingthemedicalactionabilityofgenomicvariants AT hunterjessicaezzell establishingthemedicalactionabilityofgenomicvariants |